https://orcid.org/0000-0002-8418-7145
References
- Belinchón I, Salgado-Boquete L, López-Ferrer A, et al. Dermatologists’ role in the early diagnosis of psoriatic arthritis: expert recommendations. Actas Dermosifiliogr. 2020 Dec;111(10):835–846. doi: 10.1016/j.ad.2020.06.004
- Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023 Jun;9:ard-2023–224148. doi: 10.1136/ard-2023-224148
- Gisondi P, Bellinato F, Maurelli M, et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis (Auckl). 2022 Aug 10;12:213–220. eCollection 2022. doi: 10.2147/PTT.S323300
- Savage L, Goodfield M, Horton L, et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis & rheumat. 2019;71:626–631. doi: 10.1002/art.40778
- Kampylafka E, Simon D, d’Oliveira I, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21:178. doi: 10.1186/s13075-019-1957-0
- Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73. doi: 10.1136/annrheumdis-2021-219961
- Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74–79. doi: 10.1136/annrheumdis-2021-220865.
- Rosenthal YS, Schwartz N, Sagy I, et al. Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: a nested case control study. Arthritis Rheumat. 2022 Feb;74(2):237–243. doi: 10.1002/art.41946.
- Solmaz D, Ehlebracht A, Karsh J, et al. Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence. Clin Exp Rheumatol. 2020;38(2):257–261. doi: 10.55563/clinexprheumatol/8thj0l
- Meer E, Merola JF, Fitzsimmons R, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80–86. doi: 10.1136/annrheumdis-2021-220761.
- Camela E, Potestio L, Fabbrocini G, et al. Paradoxical reactions to biologicals for psoriasis. Expert Opin Biol Ther. 2022 Dec;22(12):1435–1437. doi: 10.1080/14712598.2022.2153593
- Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: ¿An increasing challenge? Biomedicines. 2021;9(10):1482. doi: 10.3390/biomedicines9101482
- Singla S, Putman M, Liew J, et al. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5:e200–7.
- Zhou Q, Vadakekolathu J, Watad A, et al. SARS-CoV-2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights. Front Immunol. 2021;12:635018. eCollection 2021. doi: 10.3389/fimmu.2021.635018
- Ritchlin CT, Coates LC, Mease PJ, et al. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2023 Jan 10; 24(1):22. doi: 10.1186/s13063-022-06945-y